Detail

Study ID: Pfizer B9991004 Javelin Medley Solid Tumor Study

Title:

A PHASE 1B/2 OPEN-LABEL STUDY TO EVALUATE SAFETY, CLINICAL ACTIVITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF AVELUMAB* (MSB0010718C) IN COMBINATION WITH OTHER CANCER IMMUNOTHERAPIES IN PATIENTS WITH ADVANCED MALIGNANCIES

Description:
This is a Phase 1b/2 dose-optimization study to evaluate safety, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of avelumab (MSB0010718C) in combination with other cancer immunotherapies in patients with locally advanced or metastatic solid tumors. The primary purpose is to assess the safety and early signs of efficacy of various avelumab combinations with other cancer immunotherapies, optimizing dosing regimens as appropriate, in a limited series of indications. It is thought that giving avelumab with other immunotherapy drugs together may work better than giving only one drug by itself.
Location:
Sioux Falls Region
Principal Investigator:
Steven Powell, MD
Disease:
Solid Tumors
Stage:
Phase I/II
Status:
Active - Open to Accrual